Investigational drug · Phase 2
Solbinsiran
Also called: LY3561774
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Severe Hypertriglyceridemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Solbinsiran"
First trial start
2025
Dec 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Solbinsiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Severe Hypertriglyceridemia
Approved drugs for the same conditions: High triglycerides · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Solbinsiran" as an intervention, largest first.
- A Study of LY3561774 in Participants With Mixed DyslipidemiaPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05256654 · 205 participants · Start Jul 20, 2022 · Primary completion Mar 4, 2024
Drug: LY3561774; Placebo · For: Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases and 1 more
Sites: Waterbury, Connecticut; Oxon Hill, Maryland; Fall River, Massachusetts · 41 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07269210 · 60 participants (planned) · Start Dec 8, 2025 · Primary completion Mar 2027
Drug: Solbinsiran; Placebo · For: Severe Hypertriglyceridemia
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 41 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Correction: Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis.
Gao Y, Bai Y, Mu X, et al. · Front Pharmacol 2026
- Solbinsiran, a durable GalNAc-conjugated siRNA targeting ANGPTL3 in adults with mixed dyslipidaemia (PROLONG-ANG3):ߘlessons from a randomized, placebo-controlled, phase 2 trial.
Llop D, Ray KK · Cardiovasc Res 2026
- Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels.
Hegele RA · Expert Opin Ther Targets 2026
- Effect of angiopoietin-like protein 3 inhibitors on lipid profile and other biomarkers: a meta-analysis of randomized controlled trials.
Xie S, Galimberti F, Olmastroni E, et al. · Eur J Prev Cardiol 2026
- Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia.
Corral P, Nardelli N, Schreier L · Curr Opin Endocrinol Diabetes Obes 2026
- Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis.
Gao Y, Bai Y, Mu X, et al. · Front Pharmacol 2026
Also in development for Severe Hypertriglyceridemia
- DR10624Phase 35 trials
Zhejiang Doer Biologics Co., Ltd. · Severe Hypertriglyceridemia, Hypertriglyceridemia, Severe Hypertriglyceridemia (sHTG)
- PegozaferminBIO89-100Phase 33 trials
Roche (Genentech) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Severe Hypertriglyceridemia
- ION775Phase 21 trial
Ionis Pharmaceuticals · Hypertriglyceridemia, Severe Hypertriglyceridemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.